OGEN$0.37020.00%
Oragenics Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: NYSE
Mkt Cap:$1.67M
Float & O/S:
Inst Own:
DilutionScan read 18 of ORAGENICS INC's SEC filings and found 4 warrant series, 2 convertibles, 1 ATM program, 2 shelf registrations, 2 S-1 registrations and 3 completed offerings on file for OGEN. The latest dilution event on file is ATM sales on Mar 31, 2026. Analysis updated Oct 3, 2026.
Signal8 Summary
2d old
OGEN
Going-concern warning, 1.2 months of cash
- Business
- WeakZero revenue, going-concern doubt, cash funds only to Dec 2026
- Stock risk
- High$1.7M micro-cap, dilution 381% of shares, NYSE deficiency notice
Snapshot
Oragenics is a clinical-stage biotech with zero revenue, a $9.8M net loss in FY 2025, and only $3.9M of cash on hand. Management says that cash funds operations only through the end of 2026, and Signal8 models roughly 1.2 months of runway.
What's Happening Right Now
- : Oragenics' Chief Medical Officer presented on the ONP-002 intranasal concussion platform at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026; the company says this was a visibility event with no new trial data or financial figures.
- : On August 26, 2026 Oragenics received a NYSE American deficiency letter for insufficient stockholders' equity, with 45 days to submit a compliance plan and until February 25, 2028 to regain compliance; separately the company reported 9 patients dosed in its Phase IIa ONP-002 trial and is reviewing FDA Type B meeting feedback ahead of a planned year-end IND submission.
- : Oragenics' 10-Q for the period ended June 30, 2026 showed a $4.7M first-half net loss on zero revenue, cash of $3.9M expected to fund operations only through December 31, 2026, and going-concern doubt carried forward from the FY2025 audit; dilution overhang grew after the Series H conversion price was cut to $1.00 with no floor.
- : Shares traded modestly higher in mid-August 2026 trading, touching $0.5490 before settling near $0.5489 on light volume.
- : Sold $79K net / 85K shares through its at-the-market program, as stated for Mar 1, 2026 to Mar 31, 2026.
- : Registered $100.00M of securities for sale on Form S-3.
- : Closed an offering. Proceeds are not disclosed in the filings reviewed.
